JMP Securities lowered the firm’s price target on Haemonetics (HAE) to $100 from $125 and keeps an Outperform rating on the shares. Haemonetics reported an “uncharacteristically choppy” quarter, with Plasma and Hospital revenues coming in a bit below consensus, and the recently added Opsens and Attune technologies also falling a bit short of expectations, while management lowered its fiscal target growth ranges for these two divisions, the analyst tells investors in a research note. JMP still believes the company’s new products offer the most value in the plasma collection industry.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio